Literature DB >> 25022788

The prognosis of osteosarcoma occurring as second malignancy of childhood cancers may be favorable: experience of two cancer centers in Japan.

Tsukasa Yonemoto1, Ako Hosono, Shintaro Iwata, Hiroto Kamoda, Yoko Hagiwara, Tomohiro Fujiwara, Akira Kawai, Takeshi Ishii.   

Abstract

BACKGROUND: Osteosarcoma as second malignancy of childhood cancers rarely occurs, and its clinical characteristics are unclear.
METHODS: Patients with osteosarcoma occurring as second malignancy of childhood cancers were retrospectively surveyed.
RESULTS: Of 323 patients with osteosarcoma registered in the database, 10 (3.1%) had a past history of childhood cancers. The mean age at the onset of the first childhood cancer was 2.7 years, and the diagnosis of the first childhood cancer was adrenocortical carcinoma, malignant teratoma, ovarian carcinoma, Ewing's sarcoma, and rhabdomyosarcoma in 1 patient each, and retinoblastoma in 5 patients. Osteosarcoma as second malignancy occurred 14.6 years after the first childhood cancer on average. Seven patients were alive and 3 died. In 1 patient, the cause of death was related to a complication of treatment for the first childhood cancer. Except for this patient, 7 (77.8%) of 9 patients survived with no disease (mean follow-up period: 10.9 years).
CONCLUSIONS: Attention should be paid to complications of treatment for the first childhood cancer in the treatment for osteosarcoma occurring as second malignancy. The prognosis of osteosarcoma as second malignancy of childhood cancers may be more favorable than that of conventional osteosarcoma.

Entities:  

Mesh:

Year:  2014        PMID: 25022788     DOI: 10.1007/s10147-014-0729-8

Source DB:  PubMed          Journal:  Int J Clin Oncol        ISSN: 1341-9625            Impact factor:   3.402


  23 in total

Review 1.  Second primary tumors in patients with retinoblastoma. A review of the literature.

Authors:  A C Moll; S M Imhof; L M Bouter; K E Tan
Journal:  Ophthalmic Genet       Date:  1997-03       Impact factor: 1.803

2.  Second malignant neoplasms following chemoreduction with carboplatin, etoposide, and vincristine in 245 patients with intraocular retinoblastoma.

Authors:  Kiran Turaka; Carol L Shields; Anna T Meadows; Ann Leahey
Journal:  Pediatr Blood Cancer       Date:  2011-08-08       Impact factor: 3.167

3.  Second malignant neoplasms in children: an update from the Late Effects Study Group.

Authors:  A T Meadows; E Baum; F Fossati-Bellani; D Green; R D Jenkin; B Marsden; M Nesbit; W Newton; O Oberlin; S G Sallan
Journal:  J Clin Oncol       Date:  1985-04       Impact factor: 44.544

4.  Osteosarcoma as a second malignancy after treatment for neuroblastoma.

Authors:  A Iwata; T Hirota; K Konno; T Fujimoto; S Sumida; K Sato; K Hara
Journal:  Pediatr Hematol Oncol       Date:  2001 Oct-Nov       Impact factor: 1.969

5.  Second neoplasm in children treated in EORTC 58881 trial for acute lymphoblastic malignancies: low incidence of CNS tumours.

Authors:  Marleen Renard; Stefan Suciu; Yves Bertrand; Anne Uyttebroeck; Alice Ferster; Jutte van der Werff Ten Bosch; Françoise Mazingue; Emannuel Plouvier; Alain Robert; Patrick Boutard; Frédéric Millot; Martine Munzer; Françoise Mechinaud; Brigitte Lescoeur; Liliana Baila; Els Vandecruys; Yves Benoit; Pierre Philippet
Journal:  Pediatr Blood Cancer       Date:  2011-03-15       Impact factor: 3.167

6.  Combined modality treatment for osteosarcoma occurring as a second malignant disease. Cooperative German-Austrian-Swiss Osteosarcoma Study Group.

Authors:  S S Bielack; B Kempf-Bielack; U Heise; D Schwenzer; K Winkler
Journal:  J Clin Oncol       Date:  1999-04       Impact factor: 44.544

7.  Osteosarcoma as a second malignant neoplasm in children.

Authors:  J R Bechler; W W Robertson; A T Meadows; R B Womer
Journal:  J Bone Joint Surg Am       Date:  1992-08       Impact factor: 5.284

8.  Rhabdomyosarcoma, osteosarcoma, and adrenocortical carcinoma in a child with a germline p53 mutation.

Authors:  Catherine M Khayat; Donna L Johnston
Journal:  Pediatr Blood Cancer       Date:  2004-11       Impact factor: 3.167

9.  Bone sarcomas as second malignant neoplasms following childhood cancer.

Authors:  W A Newton; A T Meadows; H Shimada; G R Bunin; G F Vawter
Journal:  Cancer       Date:  1991-01-01       Impact factor: 6.860

10.  Long-term survivals of stage IIb osteosarcoma: a 20-year experience in a single institution.

Authors:  Yool Cho; Gu-Hee Jung; So-Hak Chung; Ji-Yeon Kim; Young Choi; Jae-Do Kim
Journal:  Clin Orthop Surg       Date:  2011-02-15
View more
  3 in total

Review 1.  Potential anticancer properties and mechanisms of thymoquinone in osteosarcoma and bone metastasis.

Authors:  Mina Homayoonfal; Zatollah Asemi; Bahman Yousefi
Journal:  Cell Mol Biol Lett       Date:  2022-03-02       Impact factor: 5.787

2.  A nomogram for predicting cancer-specific survival in patients with osteosarcoma as secondary malignancy.

Authors:  Yanqi He; Han Liu; Shuai Wang; Jianjun Zhang
Journal:  Sci Rep       Date:  2020-07-30       Impact factor: 4.379

3.  ML264 inhibits osteosarcoma growth and metastasis via inhibition of JAK2/STAT3 and WNT/β-catenin signalling pathways.

Authors:  Hai Huang; Ying Han; Zhijun Chen; Xin Pan; Putao Yuan; Xiangde Zhao; Hongfang Zhu; Jiying Wang; Xuewu Sun; Peihua Shi
Journal:  J Cell Mol Med       Date:  2020-04-13       Impact factor: 5.310

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.